Skip to ContentSkip to Navigation
Practical matters How to find us prof. dr. B. Horvath


Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

Clinical response to rituximab and improvement in quality of life in patients with bullous pemphigoid and mucous membrane pemphigoid

Eligibility criteria for programmed death receptor 1 inhibitors vs. real-world advice: a retrospective analysis of 69 patients with advanced cutaneous squamous cell carcinoma of the head and neck

Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial

Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study

International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients with Psoriasis

Persistent low complement levels and increased interferon gene expression are predictive for disease progression in patients with incomplete systemic lupus erythematosus

Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases

Subepidermal type VII collagen speckles as an additional clue for diagnosing epidermolysis bullosa acquisita by salt-split skin serum analysis

The positive impact of rituximab on the quality of life and mental health in patients with pemphigus

Read more